Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL W WALLACE

Allopathic & Osteopathic Physicians Dermatology

NPI
1063494474
CMS profile
184779
Location
BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20,537.26

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $13,369.72 11
AbbVie Inc. $6,471.07 25
UCB, Inc. $217.41 8
GENZYME CORPORATION $114.50 6
Lilly USA, LLC $80.08 3
Novartis Pharmaceuticals Corporation $66.82 3
PFIZER INC. $61.90 4
Almirall LLC $32.19 1
Stemline Therapeutics Inc. $30.21 1
DERMIRA, INC. $22.56 1
LEO Pharma Inc. $18.98 1
Genentech USA, Inc. $18.38 1
Janssen Biotech, Inc. $17.67 1
Galderma Laboratories, L.P. $15.77 1

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL W WALLACE

NPI 1063494474 · CMS profile ID 184779

Allopathic & Osteopathic Physicians / Dermatology

BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063494474?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL W WALLACE, NPI 1063494474, CMS profile ID 184779. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063494474?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAUL W WALLACE, NPI 1063494474, CMS profile ID 184779. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063494474?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAUL W WALLACE, NPI 1063494474, CMS profile ID 184779, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1063494474?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $20,537.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1,500.0003/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220903 CMS
Almirall LLC $32.1903/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819688371 CMS
GENZYME CORPORATION $20.9503/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843768915 CMS
AbbVie Inc. $1,500.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220901 CMS
GENZYME CORPORATION $13.4003/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843768911 CMS
Janssen Biotech, Inc. $17.6702/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788986917 CMS
Lilly USA, LLC $26.7002/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818674385 CMS
AbbVie Inc. $7.9502/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220899 CMS
UCB, Inc. $27.7702/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807295365 CMS
AbbVie Inc. $26.2502/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220897 CMS
Amgen Inc. $30.8302/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826408575 CMS
AbbVie Inc. $1,500.0002/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220895 CMS
AbbVie Inc. $7.7002/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220893 CMS
DERMIRA, INC. $22.5602/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764401368 CMS
AbbVie Inc. $14.1001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220891 CMS
AbbVie Inc. $9.2701/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796220889 CMS
Novartis Pharmaceuticals Corporation $21.6601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813347345 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $168,995.72 181
PY2020 $24,977.35 56
PY2021 $20,537.26 67
PY2022 $16,688.31 98
PY2023 $35,916.73 101
PY2024 $40,670.26 101
PY2025 $79,840.48 150

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $866,467.46 35
PY2024 Principal investigator $1,568,866.45 85
PY2023 Principal investigator $681,996.12 68
PY2022 Principal investigator $1,018,938.60 95
PY2021 Principal investigator $1,160,197.73 103
PY2020 Recipient $126.30 2
PY2020 Principal investigator $656,123.66 64
PY2019 Recipient $33,843.00 2
PY2019 Principal investigator $741,372.07 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $14,565.00 10/27/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339659
Principal investigator 1 PFIZER INC. $1,317.00 10/21/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741635
Principal investigator 1 PFIZER INC. $1,517.22 10/18/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741141
Principal investigator 1 PFIZER INC. $21,444.00 10/10/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228740626
Principal investigator 1 Janssen Research & Development, LLC $19,093.00 09/01/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339674
Principal investigator 1 PFIZER INC. $33,464.70 08/29/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719743
Principal investigator 1 PFIZER INC. $49,785.00 08/22/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766116
Principal investigator 1 Janssen Research & Development, LLC $4,045.00 07/28/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339667
Principal investigator 1 PFIZER INC. $55,974.00 07/26/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228763395
Principal investigator 1 PFIZER INC. $53,055.00 07/16/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228783816
Principal investigator 1 PFIZER INC. $4,844.34 07/15/2025 Non-covered Recipient Entity
Wallace Medical Group Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764453
Principal investigator 1 ABBVIE INC. $2,330.50 07/02/2025 Non-covered Recipient Entity
PAUL W WALLACE
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202496181
Principal investigator 1 Janssen Research & Development, LLC $21,662.00 06/30/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339645
Principal investigator 1 PFIZER INC. $7,756.08 06/25/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228790083
Principal investigator 1 ABBVIE INC. $1,494.80 06/03/2025 Non-covered Recipient Entity
PAUL W WALLACE
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202489207
Principal investigator 1 Janssen Research & Development, LLC $23,761.00 05/26/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339652
Principal investigator 1 PFIZER INC. $14,547.00 05/15/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772606
Principal investigator 1 PFIZER INC. $8,144.88 05/03/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764176
Principal investigator 1 PFIZER INC. $8,193.00 05/02/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764889
Principal investigator 1 Eli Lilly and Company $27,315.60 04/29/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187891532
Principal investigator 1 Amgen Inc. $133,974.64 04/23/2025 Non-covered Recipient Entity
PAUL WALLACE MD WALLACE MEDICAL GROUP INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246646387
Principal investigator 1 Eli Lilly and Company $9,068.55 04/22/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187893774
Principal investigator 1 PFIZER INC. $3,261.87 04/15/2025 Non-covered Recipient Entity
Wallace Medical Group Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228723052
Principal investigator 1 PFIZER INC. $5,895.00 04/08/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228779299
Principal investigator 1 PFIZER INC. $8,285.76 04/05/2025 Non-covered Recipient Entity
Wallace Medical Group Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719789
Principal investigator 1 Janssen Research & Development, LLC $37,729.00 03/24/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339682
Principal investigator 1 ABBVIE INC. $11,375.70 03/06/2025 Non-covered Recipient Entity
PAUL W WALLACE
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202458353
Principal investigator 1 PFIZER INC. $22,896.00 03/05/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228789996
Principal investigator 1 PFIZER INC. $16,533.00 03/01/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228787292
Principal investigator 1 PFIZER INC. $1,662.42 03/01/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228796398
Principal investigator 1 PFIZER INC. $26,523.00 02/08/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228757739
Principal investigator 1 PFIZER INC. $22,124.22 02/05/2025 Non-covered Recipient Entity
Wallace Medical Group INC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753706
Principal investigator 1 Janssen Research & Development, LLC $26,331.00 01/27/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175339692
Principal investigator 1 Amgen Inc. $160,180.40 01/13/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246651890
Principal investigator 1 Amgen Inc. $6,317.78 01/02/2025 Non-covered Recipient Entity
WALLACE MEDICAL GROUP INC
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246651894